{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:40:52Z","timestamp":1776724852788,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T00:00:00Z","timestamp":1493510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00277-017-3003-0","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T22:40:22Z","timestamp":1493505622000},"page":"1155-1162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5613","authenticated-orcid":false,"given":"Lukas","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hopfinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,30]]},"reference":[{"issue":"9669","key":"3003_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"C Prospective Studies","year":"2009","unstructured":"Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373(9669):1083\u20131096. doi: 10.1016\/S0140-6736(09)60318-4","journal-title":"Lancet"},{"issue":"8","key":"3003_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc1408","volume":"4","author":"EE Calle","year":"2004","unstructured":"Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579\u2013591. doi: 10.1038\/nrc1408","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3003_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3109\/10428194.2012.742523","volume":"54","author":"AV Patel","year":"2013","unstructured":"Patel AV, Diver WR, Teras LR, Birmann BM, Gapstur SM (2013) Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 54(6):1221\u20131227. doi: 10.3109\/10428194.2012.742523","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3003_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/annonc\/mdt481","volume":"25","author":"L Weiss","year":"2014","unstructured":"Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A (2014) Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 25(1):171\u2013176. doi: 10.1093\/annonc\/mdt481","journal-title":"Ann Oncol"},{"issue":"26","key":"3003_CR5","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.2011.39.2100","volume":"30","author":"KR Carson","year":"2012","unstructured":"Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang SH, Colditz GA (2012) Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 30(26):3217\u20133222. doi: 10.1200\/JCO.2011.39.2100","journal-title":"J Clin Oncol"},{"issue":"3","key":"3003_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/annonc\/mdt594","volume":"25","author":"F Hong","year":"2014","unstructured":"Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS (2014) The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol 25(3):669\u2013674. doi: 10.1093\/annonc\/mdt594","journal-title":"Ann Oncol"},{"issue":"9765","key":"3003_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","volume":"377","author":"MM Finucane","year":"2011","unstructured":"Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating G (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377(9765):557\u2013567. doi: 10.1016\/S0140-6736(10)62037-5","journal-title":"Lancet"},{"issue":"3","key":"3003_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","volume":"39","author":"G Cheymol","year":"2000","unstructured":"Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215\u2013231. doi: 10.2165\/00003088-200039030-00004","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3003_CR9","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3109\/10428194.2010.494315","volume":"51","author":"JA Jones","year":"2010","unstructured":"Jones JA, Fayad LE, Elting LS, Rodriguez MA (2010) Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51(9):1649\u20131657. doi: 10.3109\/10428194.2010.494315","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"3003_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archinte.165.11.1267","volume":"165","author":"JJ Griggs","year":"2005","unstructured":"Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165(11):1267\u20131273. doi: 10.1001\/archinte.165.11.1267","journal-title":"Arch Intern Med"},{"issue":"11","key":"3003_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/jco.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol 7(11):1630\u20131636. doi: 10.1200\/jco.1989.7.11.1630","journal-title":"J Clin Oncol"},{"issue":"9873","key":"3003_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. doi: 10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"3003_CR13","unstructured":"Non Hodgkin\u2019s Lymphomas, Version 1.2016 (2015) http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf . Accessed 05 Dec 2015"},{"key":"3003_CR14","unstructured":"Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. (0512\u20133054 (Print))"},{"issue":"1","key":"3003_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32\u201335","journal-title":"Cancer"},{"key":"3003_CR16","doi-asserted-by":"publisher","unstructured":"Monteiro R, Azevedo I (2010) Chronic inflammation in obesity and the metabolic syndrome. Mediat Inflamm 2010. doi: 10.1155\/2010\/289645","DOI":"10.1155\/2010\/289645"},{"issue":"10","key":"3003_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1937","volume":"6","author":"H Tilg","year":"2006","unstructured":"Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772\u2013783. doi: 10.1038\/nri1937","journal-title":"Nat Rev Immunol"},{"key":"3003_CR18","doi-asserted-by":"crossref","unstructured":"Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola NA, Alexander WS, Hilton DJ (1996) Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proceedings of the National Academy of Sciences of the United States of America 93 (25):14564\u201314568","DOI":"10.1073\/pnas.93.25.14564"},{"issue":"1","key":"3003_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1006\/cimm.1999.1490","volume":"194","author":"J Santos-Alvarez","year":"1999","unstructured":"Santos-Alvarez J, Goberna R, Sanchez-Margalet V (1999) Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 194(1):6\u201311. doi: 10.1006\/cimm.1999.1490","journal-title":"Cell Immunol"},{"issue":"1","key":"3003_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/cimm.1999.1594","volume":"199","author":"C Martin-Romero","year":"2000","unstructured":"Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V (2000) Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 199(1):15\u201324. doi: 10.1006\/cimm.1999.1594","journal-title":"Cell Immunol"},{"issue":"5","key":"3003_CR21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1055-9965.779.13.5","volume":"13","author":"CF Skibola","year":"2004","unstructured":"Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, Hegedus C, Smith MT (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 13(5):779\u2013786","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"4\u20135","key":"3003_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cytogfr.2005.01.010","volume":"16","author":"S Yakar","year":"2005","unstructured":"Yakar S, Leroith D, Brodt P (2005) The role of the growth hormone\/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16(4\u20135):407\u2013420. doi: 10.1016\/j.cytogfr.2005.01.010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"3003_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1182\/blood-2005-01-0306","volume":"107","author":"T Stromberg","year":"2006","unstructured":"Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, Osterborg A, Vanderkerken K, Nilsson K, Jernberg-Wiklund H (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2\/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107(2):669\u2013678. doi: 10.1182\/blood-2005-01-0306","journal-title":"Blood"},{"issue":"6","key":"3003_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3324\/haematol.2010.031567","volume":"96","author":"D Vishwamitra","year":"2011","unstructured":"Vishwamitra D, Shi P, Wilson D, Manshouri R, Vega F, Schlette EJ, Amin HM (2011) Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Haematologica 96(6):871\u2013880. doi: 10.3324\/haematol.2010.031567","journal-title":"Haematologica"},{"issue":"1","key":"3003_CR25","doi-asserted-by":"publisher","first-page":"e87474","DOI":"10.1371\/journal.pone.0087474","volume":"9","author":"Z Liang","year":"2014","unstructured":"Liang Z, Diepstra A, Xu C, van Imhoff G, Plattel W, Van Den Berg A, Visser L (2014) Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma. PLoS One 9(1):e87474. doi: 10.1371\/journal.pone.0087474","journal-title":"PLoS One"},{"issue":"12","key":"3003_CR26","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732. doi: 10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"issue":"4","key":"3003_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15(4):424\u2013435. doi: 10.1016\/S1470-2045(14)70027-0","journal-title":"Lancet Oncol"},{"issue":"9383","key":"3003_CR28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G, Hudson LDC, British National Lymphoma I (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516\u2013522","journal-title":"Lancet"},{"issue":"14","key":"3003_CR29","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C Muller","year":"2012","unstructured":"Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119(14):3276\u20133284. doi: 10.1182\/blood-2011-09-380949","journal-title":"Blood"},{"issue":"13","key":"3003_CR30","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","volume":"30","author":"JJ Griggs","year":"2012","unstructured":"Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH, American Society of Clinical O (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30(13):1553\u20131561. doi: 10.1200\/JCO.2011.39.9436","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3003-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T02:24:04Z","timestamp":1658975044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3003-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,30]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3003"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3003-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,30]]}}}